Phosphorus Announces Partnership With BioIQ to Make Phosphorus' At-Home COVID-19 Saliva Test More Accessible To People Across The Country

NEW YORK, June 17, 2020 /PRNewswire/ -- Phosphorus, a leading genomics firm headquartered in New York City with a laboratory in Secaucus, New Jersey, announced today a partnership with BioIQ, a healthcare engagement and clinical adherence technology platform company, to ensure Phosphorus' recently at-home COVID-19 saliva test is more accessible to people across the country.

The U.S. Food and Drug Administration (FDA) granted the Emergency Use Authorization request for Phosphorus' COVID-19 saliva test that features at-home sample collection. Using a saliva-based collection method is simple and less intrusive than the prevalent swab-based methods. This ease-of-use is a key characteristic to enabling the widespread and repetitive testing protocols proposed by experts to contain the COVID-19 pandemic.

BioIQ will help connect employees as well as health care plan members to this testing, an important step to re-open the country's economy. BioIQ developed a health technology platform to support digital symptom and exposure assessment, contact tracing and follow-up care navigation.

Phosphorus is also making its tests available to healthcare partners as well as to the general public by ordering online.

"Phosphorus is excited about this partnership with BioIQ. We understand that testing is essential when it comes to re-opening the economy, and this alliance will ensure that people from coast to coast have access to safe, efficient and effective COVID testing," said Alexander Bisignano, co-founder and CEO of Phosphorus.

"Additional RT-PCR COVID-19 testing capacity and convenience through home sample collection is a critical need for employers, health plans, and government agencies," said BioIQ CEO Justin Bellante. "The partnership with Phosphorus adds the sophistication and validation of a leading genomics laboratory to our network and the expanded use of home sample collection and testing for COVID-19."

Phosphorus testing protocols use strict standards to ensure accurate and reliable test results. Phosphorus is one of the first to have received Emergency Use Authorization to conduct a rigorous clinical agreement study above and beyond the synthetic sample performance study initially required by the FDA.

The company is in full compliance with FDA Guidelines for Diagnostic Tests for Coronavirus Disease-2019 during a Public Health Emergency and submitted validation data under the FDA's Emergency Use Authorization (EUA) authority. The tests were developed at Phosphorus' CLIA laboratory in Secaucus, New Jersey. OraSure's Oragene®·Dx (OGD-510) saliva collection device proved to be a reliable method for test performance comparable to gold standard methods.

Phosphorus provides advanced genomic tests using next generation sequencing (NGS) technologies to healthcare providers and hospitals. The Phosphorus laboratory is CLIA and CAP certified and licensed for testing in all 50 states. It has re-oriented its operations to focus on COVID-19 testing in order to bring its sensitive testing methodologies and extensive experience in genomics to this public health crisis.

Learn more about the Phosphorus COVID-19 Testing here.

About Phosphorus
Phosphorus's mission is to improve human health by better understanding and harnessing the power of the human genome. Having built the most comprehensive, high-quality, and cost-effective portfolio of genetic tests, Phosphorus is able to increase access and quality of care in the burgeoning field of genomics. The company currently provides panel-based, constitutional genetic testing in the specialty areas of Fertility, Cardiology, Lipidology, Oncology, Pharmacogenetics, Ophthalmology, Neurology, and Pediatric/Metabolic disorders. Phosphorus also offers the PhosphorusONE proactive health screen - the most comprehensive genomic test for taking a proactive look at your health. Additionally, Phosphorus provides the Elements(TM) software platform to enable any laboratory to easily deploy any of the Phosphorus genetic tests on-premise as a local solution. For more information, please visit our website at

About BioIQ
BioIQ is a healthcare engagement and clinical adherence technology platform company that is redefining the way payers, employers and consumers navigate and connect with the US healthcare system. BioIQ leverages consumer analytics, real-time program intelligence, omnichannel personalized engagement strategies and an extensive ecosystem of healthcare partners to provide a comprehensive view of individuals throughout their health journey and engage them to get testing and care that leads to healthier outcomes.

With more than a decade of healthcare industry experience and a first-of-its-kind health connectivity platform, BioIQ is uniquely positioned at the convergence of population health and the consumerization and retailization of healthcare to drive the shift to value-based care for payers and employers. Since 2005, BioIQ has launched thousands of successful health testing programs serving millions of participants. For more information, visit

View original content to download multimedia:

SOURCE Phosphorus